治疗相关骨髓增生异常综合征中的剪接因子3B亚基1(SF3B1)突变
在大型MDS队列中比较了新发MDS伴SF3B1突变(n=289)与治疗相关MDS伴SF3B1突变(n=31),两组基线特征、伴发突变及急性髓系白血病转化相似;治疗相关MDS伴SF3B1突变者总生存较新发者短,校正合并症后差异无统计学意义。
要点
- 治疗相关MDS伴SF3B1突变者复杂核型、TP53突变和AML转化均低于SF3B1野生型者。
- 治疗相关MDS中SF3B1突变者总生存显著长于SF3B1野生型者。
- 按IWG-PM拟议SF3B1标准,符合标准者总生存53个月,优于不符合者22个月和野生型18个月。
核心结论
- 治疗相关MDS背景下SF3B1突变患者的基线特征、伴发突变及AML转化与新发MDS伴SF3B1突变者相似,总生存差异在校正合并症后无统计学意义。
- 在治疗相关MDS中,SF3B1突变者复杂核型、TP53突变及AML转化比例均低于SF3B1野生型者,总生存显著更长。
- 按IWG-PM拟议SF3B1标准,符合标准的治疗相关MDS伴SF3B1突变者总生存显著长于不符合标准者及SF3B1野生型者,AML转化率亦显著更低。
研究设计与样本
- 基于大型MDS队列,将已知SF3B1体细胞突变者分为新发MDS(n=289)与伴SF3B1突变的治疗相关MDS(n=31)进行比较。
- 另将治疗相关MDS中SF3B1野生型(n=241)与SF3B1突变型(n=31)进行比较。
主要发现
- 新发MDS伴SF3B1突变与治疗相关MDS伴SF3B1突变两组基线特征、伴发突变及AML转化相似。
- 新发MDS伴SF3B1突变者中位总生存显著长于治疗相关MDS伴SF3B1突变者,但校正合并症后差异无统计学意义。
- 治疗相关MDS中,SF3B1野生型 vs SF3B1突变型:复杂核型37.4% vs 10.3%(p=0.009),TP53突变36.1% vs 10%(p=0.004),AML转化34.4% vs 12.9%(p=0.016)。
- 治疗相关MDS中SF3B1野生型者总生存显著短于SF3B1突变型者。
- 按IWG-PM拟议SF3B1标准,治疗相关MDS伴SF3B1突变者总生存显著短于新发MDS伴SF3B1突变者,AML转化无显著差异。
关键数值与推荐
- 治疗相关MDS中SF3B1野生型 vs 突变型:复杂核型37.4% vs 10.3%(p=0.009)。
- 治疗相关MDS中SF3B1野生型 vs 突变型:TP53突变36.1% vs 10%(p=0.004)。
- 治疗相关MDS中SF3B1野生型 vs 突变型:AML转化34.4% vs 12.9%(p=0.016)。
- 符合IWG-PM拟议SF3B1标准的治疗相关MDS伴SF3B1突变者、不符合标准者及SF3B1野生型者总生存分别为53、22和18个月(p=0.006)。
- 上述三组AML转化率分别为0%、26.7%和32.3%(p=0.021);三组无白血病生存均未达到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Splicing factor 3B subunit 1 (SF3B1) somatic mutation in the context of therapy-related myelodysplastic syndromes (t-MDS) has not been well defined. In a large cohort of patients with MDS, those with known SF3B1 somatic mutation were compared as de novo MDS (n = 289) and t-MDS with mutant SF3B1 (SF3B1mut ; n = 31). Baseline characteristics, concomitant mutations, and acute myeloid leukaemia (AML) transformation were similar between the two groups. The median overall survival (OS) of de novo MDS SF3B1mut was significantly longer compared to t-MDS SF3B1mut but not significantly different when adjusted for comorbidities. Comparing t-MDS wild-type SF3B1 (SF3B1WT ; n = 241) to t-MDS SF3B1mut (n = 31), complex cytogenetics were seen in 37.4% versus 10.3% (p = 0.009), tumour protein p53 (TP53) mutation was 36.1% versus 10% (p = 0.004), and AML transformation was 34.4% compared to 12.9% (p = 0.016) respectively. OS was significantly shorter in SF3B1WT versus SF3B1mut . When applying the International Working Group for Prognosis of MDS (IWG-PM) proposed SF3B1 criteria, OS was significantly shorter in SF3B1mut t-MDS compared to de novo MDS SF3B1mut with no significance in AML transformation. Survival was compared between t-MDS SF3B1mut who met the new proposed IWG-PM criteria to t-MDS SF3B1mut who did not meet criteria to survival of SF3B1WT t-MDS. OS was 53 versus 22 and 18 months respectively (p = 0.006). AML transformation was 0%, 26.7% and 32.3% (p = 0.021). Leukaemia-free survival was not reached among the three.
引用
- Volpe VO, Al Ali N, Chan O, et al. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. Br J Haematol. 2022. PMID: 35751140. doi:10.1111/bjh.18319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。